Clinical Trial Update: MK0354 Clinical Efficacy and Tolerability Study (0354-004) [Phase 2]

View source ↗

Summary

This update reports that the Phase 2 clinical trial of MK0354 for dyslipidemia (0354-004) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• MK0354

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dyslipidemia | Phase 2 | Status: TERMINATED